drugset
drugset / Trial / NCT00602446

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446 ↗

Phase 2 Terminated 4 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant. PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem cell transplant.

Timeline

Start
2007-08
Primary completion
2009-09
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 20 mg/kg Oral

Indications

breast cancer disorder of iron metabolism and transport leukemia myelodysplastic syndrome neuroblastoma ovarian cancer plasma cell neoplasm